Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR With Standard Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Hyaluronidase (Primary) ; Hyaluronidase/rituximab (Primary) ; Prednisone (Primary) ; Retifanlimab (Primary) ; Rituximab (Primary) ; Tafasitamab (Primary) ; Vincristine (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
Most Recent Events
- 11 Jun 2025 Planned End Date changed from 6 Jul 2026 to 6 Jul 2027.
- 11 Jun 2025 Planned primary completion date changed from 5 Jan 2026 to 5 Jan 2027.
- 07 Dec 2022 Planned initiation date changed from 15 Dec 2022 to 7 Jan 2023.